Oct 28 2013
APR announces the grant of the European CE approval of Nexodyn®, a newly developed innovative product intended for use in a variety of wound conditions such as acute wounds, burns and advanced ulcers including venous and pressure ulcers and diabetic foot ulcers. Nexodyn®, characterized by acidic and super-oxidizing features in an easy-to-use formulation, acts by improving the functional conditions of the physiological wound healing process, providing the healthcare professional and the patient with an effective, convenient and patient-friendly treatment option.
The product has been developed based on APR's proprietary technology TEHCLO®, enabling the production of acidic and super-oxidizing solutions containing free chlorine species, of which stabilized hypochlorous acid in very high concentration (> 95%).
"APR is focused on the innovative development of products covering well-defined unmet medical needs in different therapeutic areas" said Paolo Galfetti, CEO of APR. "With the approval of Nexodyn® APR is enriching its pipeline and expansion in the therapeutic area of the acute and chronic wound management, where the innovative formulation of Nexodyn® contributes to support the normal physiological healing process of advanced wounds to the final benefit of patients' quality of life. It is APR's strategic objective to register Nexodyn® in the USA and other target countries."
SOURCE APR Applied Pharma Research s.a.
Electric skin patch offers drug-free solution to bacterial infections